CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis

To evaluate CXCL10 and CCL2 in patients with hepatitis C virus chronic infection in presence/absence of autoimmune thyroiditis (AT). CXCL10 was significantly higher in: (1) patients with AT than controls without AT (control 1) (P < 0.001; ANOVA); (2) patients with hepatitis C infection than contr...

Full description

Saved in:
Bibliographic Details
Published inJournal of interferon & cytokine research Vol. 29; no. 6; pp. 345 - 352
Main Authors Antonelli, Alessandro, Ferri, Clodoveo, Fallahi, Poupak, Ferrari, Silvia Martina, Frascerra, Silvia, Pampana, Alessandro, Panicucci, Erica, Carpi, Angelo, Nicolini, Andrea, Ferrannini, Ele
Format Journal Article
LanguageEnglish
Published United States Mary Ann Liebert, Inc 01.06.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To evaluate CXCL10 and CCL2 in patients with hepatitis C virus chronic infection in presence/absence of autoimmune thyroiditis (AT). CXCL10 was significantly higher in: (1) patients with AT than controls without AT (control 1) (P < 0.001; ANOVA); (2) patients with hepatitis C infection than control 1 and patients with AT (P < 0.001); (3) patients with hepatitis C virus chronic infection and AT (HCV+AT) than control 1 and patients with AT (P < 0.001) and hepatitis C (P = 0.004). By defining a high CXCL10 level as a value >218 pg/mL, 2% of control 1, 14% of patients with AT, 68% of patients with hepatitis C infection, 81% of HCV+AT had high CXCL10 (P < 0.0001; chi-square). CCL2 was similar in control 1 and patients with AT. CCL2 was significantly higher in: (1) patients with hepatitis C infection than control 1 (P = 0.04; ANOVA); (2) HCV+AT than patients with AT (P = 0.03) and control 1 (P = 0.02); no difference was observed between HCV with or without AT. Our study demonstrates: (1) higher circulating CXCL10 and CCL2 in patients with hepatitis C virus chronic infection than in controls; (2) higher CXCL10 in HCV+AT than in patients with hepatitis C infection, suggesting a stronger Th1 immune response in these patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1079-9907
1557-7465
DOI:10.1089/jir.2008.0090